Ms. Falberg has served as a member of the Arcus board since September 2017. Previously she served as EVP and CFO of Jazz Pharmaceuticals and was responsible for strategy, corporate development, corporate communications, and information technology. …Ms. Falberg is currently on the Board of Directors for Aimmune Therapeutics, aTyr Pharma, Axovant Sciences, and The Trade Desk, and recently served on the Board of Directors of Medivation until its acquisition by Pfizer.
Juan Jaen, PhD
Dr. Jaen has been engaged in all aspects of drug discovery and development for more than 30 years, and in 2015 he co-founded Arcus. Before starting Arcus, Dr. Jaen was co-founder and President of Flexus Biosciences. He was Chief Scientific Officer and SVP of Drug Discovery at ChemoCentryx for 7 years, … where he led the discovery and progression into the clinic of 8 novel immunology drug candidates. Dr. Jaen has also held various positions at Amgen, Tularik, and Parke-Davis/Warner-Lambert. He is an inventor on 50 patents and has helped the advancement of over 20 novel molecules into clinical development across a range of indications.
Ms. Jarrett is an accomplished executive in the healthcare and technology industries. She most recently served as Vice President of Corporate Development and Capital Markets of Uber Technologies, Inc., and prior to this, was Chief Operating Officer and Chief Financial Officer of Arcus Biosciences. Ms. Jarrett has been an ongoing member… of Arcus’s board of directors since January 2019. Prior to Arcus, Ms. Jarrett was Chief Financial Officer of Medivation, a commercial oncology company that developed XTANDI®️ (enzalutamide), which has become an established standard-of-care therapy for the treatment of prostate cancer. Ms. Jarrett spent 20 years in investment banking, including an extensive tenure at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Ms. Jarrett also serves on the boards of Syndax Pharmaceuticals and Arena Pharmaceuticals.
Yasunori Kaneko, MD
Dr. Kaneko has served as a member of the Arcus board since May 2015. He is currently the Managing Director at Skyline Venture Partners and was previously the CFO and VP, Business Development at Tularik. Dr. Kaneko has also served as SVP and CFO of Ionis Pharmaceuticals. …He currently serves as a member of the Dean of Research Advisory Council at Stanford University.
David Lacey, MD
Dr. Lacey has had a distinguished academic and highly accomplished biopharmaceutical industry career discovering and creating life-changing and critical quality of life improvement therapies for patients. …During his 17-year tenure at Amgen, Dr. Lacey oversaw Amgen’s Discovery Research organization during a key period in the company’s history, leading more than 1,200 scientists across a portfolio of drug discovery and development projects in the therapeutic areas of hematology/oncology, inflammation, metabolicdisorders, and neuroscience.
At Amgen, Dr. Lacey helped make significant advancements in the understanding of bone biology, playing a fundamental role in the discovery of osteoprotegerin (OPG) and in the understanding of the RANK/RANK ligand pathway in bone metabolism that paved the way for the development of Prolia® (denosumab) for osteoporosis and XGEVA® for cancer-related bone diseases, which had combined annual sales of more than $2 billion. Denosumab has received a number of awards including the US 2011 Prix Galien award for best new biotechnology product. Dr. Lacey also initiated the clinical studies of keratinocyte growth factor (KGF), which ultimately was approved as Kepivance® (palifermin) for chemotherapy patients with severe oral mucositis. Prior to joining Amgen, Dr. Lacey was on the faculty at Washington University Medical Center in St. Louis, Missouri where he taught pathology residents and medical students, performed professional medical service in anatomic pathology, and pursued NIH-funded research in bone cell biology.
Dr. Lacey received his bachelor’s degree in biology and his M.D. degree from the University of Colorado where he served as Chief Resident of Anatomic Pathology in his final year of training. He is board certified in anatomical pathology. Dr. Lacey currently serves as a Board member for several biotech companies and acts as an esteemed advisor to a number of academic institutions, biotechnology companies, and venture capital firms.
Patrick Machado, JD
Mr. Machado has served as a member of the Arcus board since December 2019. He has more than 20 years of experience growing biopharmaceutical organizations from development through commercialization. He co-founded and served as CFO and CBO at Medivation until his retirement and served as a member of Medivation’s Board of Directors… until its acquisition by Pfizer. During his tenure, the company saw substantial growth and the commercial launch of Xtandi®. Prior to Medivation, Mr. Machado worked to expand access to national health plans in the US.
Merdad Parsey, MD, PhD
Dr. Parsey is currently the Chief Medical Officer of Gilead Sciences, where he is responsible for overseeing Gilead’s global clinical development and medical affairs organizations. Prior to joining Gilead, Dr. Parsey served as Senior Vice President of Early Clinical Development at Genentech, where he led clinical development for areas including …inflammation, oncology and infectious diseases. Prior to Genentech, Dr. Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences). Prior to Sagimet BioSciences, Dr. Parsey held development roles at Sepracor, Regeneron and Merck and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado. He currently also serves on the Board of Directors for Sagimet BioSciences.
Andy Perlman, MD, PhD
Dr. Perlman has been a long-time leader in the biotechnology field. Dr. Perlman served as Senior Director of Clinical Research at Genentech contributing to their early success, including playing a key role in the development, FDA approval and marketing of Nutropin® (somatropin). … He was one of the first hires at Tularik, with a broad array of responsibilities that early on included clinical trial design and implementation, ultimately expanding to include key roles in Tularik’s business development, investor relations and financing activities, culminating with Tularik’s acquisition by Amgen in 2004. Dr. Perlman’s experience also included serving as CEO of Affymax. He is currently Managing Director and Head of non-clinical Development of X-37, LLC, an artificial intelligence-enabled drug discovery company, as well as the Chief Medical Officer and Managing Director of Velocity Pharmaceutical Development. Dr. Perlman earned his M.D. and Ph.D. degrees from New York University, and carried out post-doctoral research in the laboratory of Nobel Laureate Professor Eric Kandel. He completed his post-graduate clinical training at NYU and Stanford School of Medicine.
Michael Quigley, PhD
Dr. Quigley has spent his entire career focused on oncology drug discovery, both on the preclinical and translational fronts of the field. He is currently the Senior Vice President of Research Biology at Gilead Sciences, overseeing the company’s biology teams and preclinical programs as well as protein biotherapeutics and computational biology and bioinformatics efforts across all therapeutic areas. … Prior to that, he was Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center at Bristol-Myers Squibb and site head of the company’s Redwood City, California location. In that role, Dr. Quigley was responsible for setting strategy for Bristol-Myers Squibb’s oncology discovery portfolio and business development activities, overseeing target identification, validation and preclinical development of large and small molecule therapies, with focus on developing new therapies at the intersection of tumor, stromal and immune biology within the tumor microenvironment to enhance responsiveness to checkpoint blockade and other targeted therapies. Dr. Quigley previously worked in oncology discovery at MedImmune and Janssen. Dr. Quigley earned his Ph.D. degree in Immunology from Duke University and conducted post-doctoral research at the Dana Farber Cancer Institute, Department of Pediatric Oncology. He serves on the Scientific Advisory Board of the Keystone Symposia as well as Enara Bio and on the Board of Directors for Pionyr Immunotherapeutics.
Antoni Ribas, MD, PhD
Dr. Ribas is an internationally recognized physician-scientist who conducts translational and clinical research to understand how the immune system can be used to treat cancer. He has been a leader in the research and clinical development of multiple types of therapeutic agents, including immune checkpoint inhibitors, gene-engineered …T cells, and BRAF-targeted therapies. Dr. Ribas has served as principal investigator for multiple trials, including those involving pembrolizumab. Dr. Ribas is a Professor at UCLA, Director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center, and Director of the UCLA Parker Institute for Cancer Immunotherapy Center. He is currently the President-Elect for the American Association of Cancer Research.
Terry Rosen, PhD
Chief Executive Officer
Dr. Rosen has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for more than 30 years. In 2015, he co-founded Arcus, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, Dr. Rosen was co-founder and CEO of Flexus Biosciences, … focusing on small molecule drugs that reverse tumor immunosuppression. He has held several executive positions at Amgen and Tularik, as well as scientific and management positions at Pfizer and Abbott Laboratories. Dr. Rosen also serves on the boards of scientific institutions such as the Salk Institute Board of Trustees and the Caltech Biology & Engineering Chair’s Council.